Relative Bioavailability Study of a Tablet Formulation vs. Pediatric Granule Formulation of Dolutegravir 50 mg and Effect of Different Types of Water Plus Infant Formula on the Pediatric Granule Formulation in Healthy Male and Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2013
At a glance
- Drugs Dolutegravir (Primary)
- Indications Herpesvirus infections; HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 25 Nov 2013 Results published in Antiviral Therapy.
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 15 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History